Early-phase (I/IIa) clinical trials for psychedelic drugs typically utilize healthy subjects, though follow-up studies with clinical populations or inclusion of neuroscientific measures in later-phase trials are desirable.

Authors

• Person: Not available Organization: Nature
  Neuroimaging in psychedelic drug development: past, present, and ...

Sources

• Neuroimaging in psychedelic drug development: past, present, and ... www.nature.com Nature via serper

Referenced by nodes (2)

• psychedelic drugs concept
• clinical trials concept